Dual inhibition of carbonic anhydrases VA and VII by silychristin and isosilybin A from Silybum marianum : A potential antiobesity strategy
Archiv der Pharmazie · 2025-03 · 358 (3)
DOI: 10.1002/ardp.202400966 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 24.03.2025. Verfasst von Emanuele Liborio Citriniti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze della Salute, Università "Magna Græcia" di Catanzaro, Catanzaro, Italy. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Carbonic Anhydrase Inhibitors, Silymarin, Carbonic Anhydrases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PON "Ricerca e Innovazione" 2014-2020, grant number No. 26" code DOT13C5773-4.
Abstract (Originalsprache)
Obesity is a global health crisis linked to chronic diseases like cardiovascular disease and type 2 diabetes. Its prevalence, even in low‐income countries, highlights the failure of traditional interventions. Safer pharmacological treatments are urgently needed, as many existing antiobesity drugs have been withdrawn due to severe side effects, leaving a critical therapeutic gap. A promising target in this context is human carbonic anhydrase V ( h CA V), a mitochondrial enzyme that plays a key role in glucose homeostasis. Inhibiting h CA V has been shown to reduce lipogenesis and improve metabolic conditions. Natural plant extracts, such as silymarin from milk thistle, have demonstrated potential in managing obesity‐related metabolic syndromes by lowering triglycerides, reducing cholesterol levels, and improving liver function. Our computational studies have identified active compounds in silymarin that effectively inhibit h CA V, shedding light on a potential mechanism for its antiobesity effects. Building on these findings, our research further reveals that these compounds also inhibit carbonic anhydrase VII ( h CA VII), enhancing their therapeutic potential. This dual inhibitory action addresses both metabolic dysregulation and oxidative stress. Notably, the antioxidant properties of h CA VII provide additional protection against obesity‐related complications by mitigating oxidative stress, a key contributor to the development of metabolic syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienze della Salute, Università "Magna Græcia" di Catanzaro, Catanzaro, Italy.
- Net4Science S.r.l., Università "Magna Græcia" di Catanzaro, Catanzaro, Italy.
- Associazione CRISEA-Centro di Ricerca e Servizi Avanzati per l'Innovazione Rurale, Catanzaro, Italy.
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Florence, Italy.
Förderung
- PON "Ricerca e Innovazione" 2014-2020, grant number No. 26" code DOT13C5773-4
Zitieren
APA
Citriniti, E. L., Rocca, R., Costa, G., Renzi, G., Carta, F., Supuran, C. T., Alcaro, S., & Ortuso, F. (2025). Dual inhibition of carbonic anhydrases VA and VII by silychristin and isosilybin A from Silybum marianum : A potential antiobesity strategy. Archiv der Pharmazie, 358(3). https://doi.org/10.1002/ardp.202400966
Vancouver
Citriniti EL, Rocca R, Costa G, Renzi G, Carta F, Supuran CT, et al. Dual inhibition of carbonic anhydrases VA and VII by silychristin and isosilybin A from Silybum marianum : A potential antiobesity strategy. Archiv der Pharmazie. 2025;358(3). doi:10.1002/ardp.202400966
BibTeX
@article{Citriniti2025,
author = {Citriniti, Emanuele Liborio and Rocca, Roberta and Costa, Giosuè and Renzi, Gioele and Carta, Fabrizio and Supuran, Claudiu T and Alcaro, Stefano and Ortuso, Francesco},
title = {Dual inhibition of carbonic anhydrases VA and VII by silychristin and isosilybin A from Silybum marianum : A potential antiobesity strategy},
journal = {Archiv der Pharmazie},
year = {2025},
volume = {358},
number = {3},
doi = {10.1002/ardp.202400966}
}
EUVIMED